

Other Notifications, Orders etc.

Government of Pakistan
Ministry of National Health Services, Regulations and Coordination
(Drug Regulatory Authority of Pakistan)

Islamabad, the 7th December, 2016

NOTIFICATION

F.No.9-12/2014-DDC(P)(Vol-III). In pursuance of sub-clause (vii) of clause (c) of section 7 of the Drug Regulatory Authority of Pakistan Act, 2012 (XXI of 2012) read with para 13(3) of the Drug Pricing Policy-2015, the Federal Government, on the recommendation of the Policy Board, is pleased to add the under mentioned molecules after S.No.323 of the schedule to the Drug Pricing Policy-2015 namely:

S.No.	Molecule	Therapeutic use / Indication
324.	Aflibercept	Biological drug; used for the treatment of wet macular degeneration of eye.
325.	Belimumab	Biological drug used in the treatment of systemic lupus erythematosus.
326.	Apixaban	Anticoagulant for the treatment of venous thromboembolic events.
327.	Denosumab	Biological drug; used for those with osteoporosis at high risk for fractures, bone loss due to certain medications, and in those with bone metastases.
328.	Daclizumab	Biological drug; used in Organ Transplant.
329.	Colfosceril Palmitate (Exosurf)	Biological drug; used as lung's surfactant.
330.	Pegfilgrastim	Biological drug; used to stimulate the level of white blood cells.
331.	Methoxy Polyethylene Glycerol Epotin Beta	Biological drug ; used to increase red blood cells.
332.	Lenograstim	Biological drug; used as immunomodulator.
333.	Tacrolimus	Used in Organ Transplant.
334.	Everolimus	Anti-cancer.
335.	Botulinum Toxin (all types)	Biological drug; used in various medical problems.


Amanullah

Director, Costing & Pricing